Areteia Therapeutics
Durham, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $75M
Overview
Advancing dexpramipexole, a novel oral therapy to lower eosinophils for allergic and inflammatory diseases.
RespiratoryImmunology
Technology Platform
A clinical-stage oral small molecule, dexpramipexole, that reduces blood and tissue eosinophil counts by inhibiting their maturation in the bone marrow.
Funding History
1Total raised:$75M
Series A$75M
Opportunities
Potential to become a foundational, convenient oral therapy for eosinophilic diseases, capturing significant market share from more invasive biologic injections.
Risk Factors
Clinical risk that Phase 3 trials may not confirm earlier efficacy signals, and commercial risk from established biologic competitors with strong physician familiarity.
Competitive Landscape
In EoE, competes against injectable biologics (e.g., dupilumab) by offering a convenient oral alternative, though with a systemic rather than targeted mechanism.